Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models

21 Aug 2016

Abstract excerpt

Adoptive immunotherapy is a potentially curative therapeutic approach for patients with advanced cancer. However, the in vitro expansion of antitumor T cells prior to infusion inevitably incurs differentiation towards effector T cells and impairs persistence following adoptive transfer. Epigenetic profiles regulate gene expression of key transcription factors over the course of immune cell differentiation,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27548527
DOI: 10.1172/jci86437

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy modelsPMID 27548527Read ↗

Bromodomain protein BRD4 directs and sustains CD8 T cell differentiation during infectionSemantic proximity Read ↗

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1Semantic proximity Read ↗

Decoding and overcoming T cell exhaustion: Epigenetic and transcriptional dynamics in CAR-T cells against solid tumorsSemantic proximity Read ↗

Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapySemantic proximity Read ↗

Domain-selective targeting of BET proteins in cancer and immunological diseasesSemantic proximity Read ↗

BET inhibitors synergize with anti-PD1 by rescuing TCF1 <sup>+</sup> progenitor exhausted CD8 <sup>+</sup> T cells in Acute Myeloid LeukemiaSemantic proximity Read ↗

Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in miceSemantic proximity Read ↗

Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseasesSemantic proximity Read ↗

BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in miceSemantic proximity Read ↗

The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous ProteinsSemantic proximity Read ↗

Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasmsSemantic proximity Read ↗

A Novel CREBBP/p300 Activator, YF2, Enhances Cytotoxic and Immune-Mediated Responses in B-Cell LymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.